RecruitingNCT02630615

Circulating Tumor Cells (CTC) in Lung Cancer


Sponsor

Shadia Jalal

Enrollment

80 participants

Start Date

Oct 19, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Histologically or cytologically confirmed lung cancer (both non-small cell lung cancer and small cell lung cancer are allowed)
  • Stage 4 NSCLC or extensive-stage SCLC
  • Newly diagnosed disease with no prior systemic therapy for advanced disease Note: Patients that have received prior adjuvant chemotherapy or prior chemoradiotherapy for earlier stage lung cancer are allowed if treatment was completed ≥3 months.
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent document
  • Inclusion of Women and Minorities Both men and women of all races and ethnic groups are eligible for this study.

Interventions

OTHERBlood draw

Whole blood will be collected using standard phlebotomy procedures


Locations(2)

Indiana University Health Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Roudebush VA Medical Center

Indianapolis, Indiana, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02630615


Related Trials